ReviewDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2024
History and evidence for state of the art of lymphadenectomy in esophageal cancer surgery.
Review in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Multicentre randomized clinical trial on robot-assisted versus video-assisted thoracoscopic oesophagectomy (REVATE trial).The British journal of surgery · 2024Trial
- Article
- Spatial nodal pattern refines disease-free survival stratification beyond pathological N stage in resected esophageal squamous cell carcinoma.BMC cancer · 2026Article
- Tailoring the Extent of Lymphadenectomy for Esophageal Squamous Cell Carcinoma: Insights From a Comparative Study of Neoadjuvant Chemo-Immunotherapy and Surgery Cohort.Thoracic cancer · 2026Article
- Prognostic impact of treatment modalities and examined lymph nodes count on survival in T3-4 esophageal cancer: a retrospective cohort and predictive modeling study from the Surveillance, Epidemiology, and End Results database.Journal of thoracic disease · 2026Article
- The Prognostic Role of Lymphadenectomy during Esophagectomy for Esophageal Cancer with Complete or Near-Complete Tumor Response after Neoadjuvant Therapy.Annals of surgical oncology · 2026Article
- Additional chemoradiotherapy versus esophagectomy for early esophageal cancer: an integrated analysis of reconstructed time-to-event data.Therapeutic advances in gastroenterology · 2026Article
- Perioperative outcomes and survival of indocyanine green-guided minimally esophagectomy in patients with esophageal cancer: a retrospective comparison study.Quantitative imaging in medicine and surgery · 2026Article
- Observational
- Sentinel Lymph Node Mapping in Esophageal Cancer: Current Status and Future Directions.Annals of surgical oncology · 2025Review
- The impact of extended lymphadenectomy on survival in esophageal adenocarcinoma with complete pathologic response: a retrospective study.Journal of thoracic disease · 2025Article
- Review
- Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma.The British journal of surgery · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current curative multimodal treatment of advanced esophageal cancers consists of neoadjuvant or perioperative chemo(radio)therapy followed by a radical surgical resection of the primary tumor and a 2- or 3-field lymphadenectomy. One of the most important predictors of long-term survival of esophageal cancer patients is lymph node involvement. The distribution pattern of lymph node metastases in esophageal cancer is unpredictable and depends on the primary tumor location, histology, T-stage and application of neoadjuvant or perioperative treatment. The optimal extent of the lymphadenectomy remains controversial; there is no global consensus on this topic yet. Some surgeons advocate an aggressive and extended lymph node dissection to remove occult metastatic disease, to optimize oncological outcomes. Others promote a more restricted lymphadenectomy, since the benefit of an extended lymphadenectomy, especially after neoadjuvant chemoradiotherapy, has not been clearly demonstrated, and morbidity may be reduced. In this review, we describe the development of lymphadenectomy, followed by a summary of current evidence for lymphadenectomy in esophageal cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.